CoChat

Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives

Open access
Pardo-Moreno, Teresa, González-Acedo, Anabel, Rivas-Domínguez, Antonio, García-Morales, Victoria, García-Cozar, Francisco Jose, Ramos-Rodríguez, Juan Jose, Melguizo-Rodríguez, Lucía · 2022 · Pharmaceutics

The DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14061117

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Drugs approved for the treatment of Alzheimer’s disease: mechanisms of action, weight, and molecular structure.
Figure 1 Drugs approved for the treatment of Alzheimer’s disease: mechanisms of action, weight, and molecular structure.CC BY · PubMed Central
Figure 2 Molecular pathways involved in the pathology and in treatments under investigation for AD.
Figure 2 Molecular pathways involved in the pathology and in treatments under investigation for AD.CC BY · PubMed Central
Figure 3 Diagram of protective and risk factors associated with Alzheimer’s disease.
Figure 3 Diagram of protective and risk factors associated with Alzheimer’s disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Buchanan, T., De Bruyn, S., Fadini, T., Watanabe, S., Germani, M., and Mesa, A.B.I.R. (2019, January 22–26). A Randomised, Placebo-Controlled, First-in-Human Study with a Central Tau Epitope Antibody–UCB0107. Proceedings of the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France.

Cited by

See all 239

Metadata

Authors
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L.
Affiliations
  • Instituto Nacional de Gestión Sanitaria (INGESA), Primary Health Care, 51003 Ceuta, Spain
  • Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences (Melilla), University of Granada, 52005 Granada, Spain
  • Universidad de Sevilla (ES)
  • Department of Biomedicine, Biotechnology and Public Health, Physiology Area, Faculty of Medicine, University of Cádiz, Pl. Falla, 9, 11003 Cádiz, Spain
  • Department of Biomedicine, Biotechnology and Public Health, Immunology Area, University of Cádiz Pl. Falla, 9, 11003 Cádiz, Spain
  • Department of Physiology, Faculty of Health Sciences (Ceuta), University of Granada, 51001 Ceuta, Spain
  • Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-05-24
Volume
14
Issue
6
Pages
1117
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4281488754
Cited by
239
References
158
Citations by year
2026: 52 · 2025: 62 · 2024: 66 · 2023: 48 · 2022: 11
FWCI
6.44
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
  • RODIN (Universidad de Cádiz) (submittedVersion, cc-by)
Funders
  • Junta de Andalucía, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
  • the Ministry of Science and Innovation, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, amyloid-beta, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, aducanumab, donepezil, galantamine, rivastigmine, memantine, gamma-secretase inhibitors, beta-secretase inhibitors, aggregation inhibitors, amyloid-beta clearance, tau aggregation inhibitors, dementia treatment, lifestyle intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.